MWN-109 in Diabetes Mellitus, Type 2: NCT07801326 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Completed
Recruitment status
162
Planned enrollment
2026-08-10
Primary-completion proxy
Executive view
NCT07801326 evaluates MWN-109 in Diabetes Mellitus, Type 2. The disclosed sponsor is Shanghai Minwei Biotechnology Co., Ltd, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Maximum Concentration (Cmax), assessed over From Day 1 to Day 29.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07801326 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Diabetes Mellitus, Type 2 landscape. Drug & Asset MCP drug_fetch was queried for MWN-109, while Company & Deal Intelligence MCP organization_fetch was queried for Shanghai Minwei Biotechnology Co., Ltd.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07801326 | MWN-109 | Phase 1 / Completed | Shanghai Minwei Biotechnology Co., Ltd | China | Maximum Concentration (Cmax) From Day 1 to Day 29 | 2026-08-10 |
| NCT07812636 | Tirzepatide | Early Phase 1 / Not yet recruiting | Hershey Medical Center | United States | Pathologic Response at 6 months from Cycle 1 Day 1 At the end Cycle 6 Day 28 (Approximately 6 months from Cycle 1 Day 1w… | 2028-05-01 |
| NCT07807059 | HRS-4729 | Phase 1 / Not yet recruiting | Fujian Suncadia Pharmaceuticals Co Ltd. | China | Cmax assessed up to approximately 4 weeks post-dose; | 2027-03-15 |
| NCT07803809 | MWN105 | Phase 1 / Recruiting | Shanghai Minwei Biotechnology Co., Ltd | China | Incidence of adverse events (AEs) and serious adverse events (SAEs) From Day 1 to Day 78 | 2026-10-01 |
| NCT07801313 | MWN105 | Phase 1 / Completed | Shanghai Minwei Biotechnology Co., Ltd | China | Incidence of adverse events (AEs) From Day 1 to Day 50 | 2025-07-20 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07801326 is a Phase 1, completed study with 162 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Maximum Concentration (Cmax)” over “From Day 1 to Day 29.” The retrieved endpoint description is: Cmax of MWN109..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 162 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Diabetes Mellitus, Type 2. These records do not establish direct evidence for NCT07801326 unless the registration number matches.
A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhib…
Phase 2; n=39; Absolute Change in HbA1c(Least Squares Mean) = 0.16 percentage of glycosylated hemoglobin (95% Confidence Interval, -0.32 to 0.63); Absolute Change in HbA1c(Least Squares Mean) = -1.11 percentage of glycosylated hemoglobin (95% Confidence Interval, -1.6 to -0.62) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232071
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweigh…
Phase 3; n=1613; Percent Change From Baseline in Body Weight(Least Squares Mean) = -2.21 percent change (Standard Error, 0.215); Percent Change From Baseline in Body Weight(Least Squares Mean) = -5.50 percent change (Standard Error, 0.356) Source: https://clinicaltrials.gov/ct2/show/results/NCT05872620
A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With…
Phase 2; n=1; Other (Not Including Serious) Adverse Events = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT07030868
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
MWN-109 is indexed as Synthetic peptide with GCGR x GIPR x GLP-1R biology and a global stage of Phase 3. The asset profile lists Shanghai Minwei Biotechnology Co., Ltd as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Shanghai Minwei Biotechnology Co., Ltd. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether MWN-109 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07801326
Protocol source: https://clinicaltrials.gov/study/NCT07801326
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
MWN-109 in Diabetes Mellitus, Type 2 is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Maximum Concentration (Cmax) and 2026-08-10 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
